Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

October 17, 2024 8:45 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has entered into a Materials Transfer Agreement with Tokyo Medical University to advance the development of its systemic DNase program.Under the terms of the agreement, Professor Takuro Nakamura of the Department of...

Read more

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

October 17, 2024 8:30 AM

- Company Expands Phase 2 trial to Canada -POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia.Agitation affects between 40-80% of Alzheimer's patients...

Read more

Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells

October 16, 2024 9:00 AM

LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today announced topline results for the company's Phase 1 clinical trial of ATH-063, an investigational oral small molecule G9A inhibitor and the company's lead asset in development for the treatment of...

Read more

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

October 16, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance...

Read more

Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes

October 15, 2024 8:00 AM

A Phase I/II Clinical Study to assess safety, potency and durability of SR-02 implanted to the abdominal omentum of patients with difficult-to-control T1DGERMANTOWN, MD / ACCESSWIRE / October 15, 2024 / Seraxis Inc., a clinical-stage regenerative medicine company, has received the FDA's allowance of an Investigational New Drug (IND) application for a Phase I/II clinical study of its novel islet replacement therapy SR-02. SR-02 is the first...

Read more

GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug

October 15, 2024 7:00 AM

As a part of their Exclusive Licensing Deal, EndoPure Life Sciences will finance and sponsor first-in-human clinical trials, which help to advance GB Sciences' cannabinoid-based products globally.LAS VEGAS, NV / ACCESSWIRE / October 15, 2024 / GB Sciences, Inc. (OTCQB:GBLX), a leading data-driven, plant-inspired biopharmaceutical development company, has signed an exclusive licensing deal with EndoPure Life Sciences, LLC, a company with...

Read more

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

October 9, 2024 5:35 PM

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024.Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason...

Read more

Canyon Labs Expands Capabilities With Acquisition of Life Pack Labs

October 8, 2024 9:00 AM

Utah-based Canyon Labs announces its strategic acquisition of Life Pack Labs in California, broadening its service offerings and enhancing its position as an industry leader in medical device and pharmaceutical compliance testing.SALT LAKE CITY, UT / ACCESSWIRE / October 8, 2024 / Canyon Labs, a leading medical device & pharmaceutical consulting, sterility assurance, analytical chemistry and package testing provider, is proud to announce the...

Read more

Kelly Keegan Joins Qr8 Health as Chief Commercial Officer

October 8, 2024 9:00 AM

Keegan to Lead Strategic Growth and Drive AI-Enabled Innovation in Digital Cognitive Health SolutionsCLEVELAND, OH / ACCESSWIRE / October 8, 2024 / Qr8 Health announced the appointment of Kelly Keegan as Chief Commercial Officer (CCO). Keegan brings more than 30 years of experience as a dynamic and entrepreneurial leader in the healthcare industry. His career is marked by significant contributions to building and expanding organizations in...

Read more

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

October 8, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, will present at the 18th Annual Pain Therapeutics Summit taking place on October 28 and 29, 2024 in Boston, MA.Dr. Kirkpatrick's presentation "When...

Read more

Next Gen Diagnostics Announces Agreement to Develop Sequence-Based Susceptibility Determination of Cefiderocol

October 7, 2024 8:00 AM

CAMBRIDGE, MA / ACCESSWIRE / October 7, 2024 / Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence-based determination of bacterial susceptibility to antibiotics, announces an agreement with Shionogi & Co., Ltd. (Shionogi) to develop models to predict susceptibility to cefiderocol. Shionogi is a global research-driven pharmaceutical company based in Japan and is the...

Read more

FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer

October 7, 2024 7:30 AM

KØBENHAVN, DK / ACCESSWIRE / October 07, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biothech company specializing in precision cancer surgery, today announced the submission of the Clinical Trial Application (CTA) for phase II trial in head and neck cancer (oral squamous cell carcinoma cancer). Redeye will host a live streaming event regarding the head and neck trial on 18 October 2024,...

Read more

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

October 3, 2024 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database. IGC Pharma, Inc. The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institutes of Health ("NIH"). The competition...

Read more

CB Scientific, Inc. Appoints Trip Thomas as Chief Financial Officer

October 3, 2024 9:00 AM

LAS VEGAS, NV / ACCESSWIRE / October 3, 2024 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced today that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation...

Read more

Biovica Announces Outcome of Exercise of Warrants of Series To 3 B

October 3, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / October 3, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica International AB ("Biovica" or the "Company") announces today the outcome of the exercise of warrants of series TO 3 B issued in connection with the Company's rights issue of units during October 2023. In total, 7,441,387 warrants were exercised for subscription of the equivalent amount of class B shares in the Company,...

Read more

SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space

October 2, 2024 10:00 AM

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has filed new provisional patent application with USPTO.Dr. David Aguilar, COO, SOHM, Inc. announced that the company has filed a new provisional application entitled;"DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING"Dr. Aguilar further added that the application...

Read more

Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit

October 2, 2024 10:00 AM

DELRAY BEACH, FL / ACCESSWIRE / October 2, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy C. Levitt, MD, the Company's founder, Chief Medical Officer, and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at...

Read more

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

October 2, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a response from Chief Executive Officer, Dr. Lynn Kirkpatrick, regarding recent inquiries from stockholders and other interested parties.Dear Fellow Stockholders,It is important to me to directly deliver an update...

Read more

Moolec Science Presents Fiscal Year 2024 Annual Business Update

October 2, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows:GLASO™: The Company announced an offtake agreement with...

Read more

Adnexus Biotechnologies Unveils Sutra(TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research

October 1, 2024 8:00 AM

DALLAS, TX / ACCESSWIRE / October 1, 2024 / Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research, is pleased to announce its new AI Empowered Drug Discovery Platform, Sutra™. The Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their...

Read more